BIA
CPRX icon

Bell Investment Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Bell Investment Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.6K Buy
307
+197
+179% +$4.69K ﹤0.01% 793
2025
Q4 		$2.57K Sell
110
-24
-18% -$535 ﹤0.01% 1259
2025
Q3 		$2.64K Sell
134
-67
-33% -$1.38K ﹤0.01% 1217
2025
Q2 		$4.36K Buy
201
+43
+27% +$1.01K ﹤0.01% 1045
2025
Q1 		$3.83K Buy
158
+23
+17% +$518 ﹤0.01% 1033
2024
Q4 		$2.82K Buy
135
+17
+14% +$365 ﹤0.01% 1196
2024
Q3 		$2.35K Hold
118
– – ﹤0.01% 1283
2024
Q2 		$1.83K Hold
118
– – ﹤0.01% 1387
2024
Q1 		$1.88K Sell
118
-43
-27% -$648 ﹤0.01% 1386
2023
Q4 		$2.71K Sell
161
-36
-18% -$492 ﹤0.01% 1199
2023
Q3 		$2.3K Buy
+197
New +$2.63K ﹤0.01% 1196
2023
Q2 		– Sell
-39
Closed -$647 – 1936
2023
Q1 		$647 Hold
39
– – ﹤0.01% 1704
2022
Q4 		$725 Hold
39
– – ﹤0.01% 1670
2022
Q3 		$1K Buy
+39
New +$462 ﹤0.01% 1361

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bell Investment Advisors's CPRX Position: Q1 2026 in Review

Bell Investment Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 179% in Q1 2026, buying an estimated $4.69K and bringing the position to 307 shares worth $7.6K. The position accounts for ﹤0.01% of the portfolio, ranked #793.

Bell Investment Advisors first reported a position in CPRX in Q3 2022 and has held it in 14 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Bell Investment Advisors held 307 shares of Catalyst Pharmaceutical worth $7.6K as of Q1 2026.
  • Bell Investment Advisors bought 197 Catalyst Pharmaceutical shares in Q1 2026, an estimated $4.69K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Bell Investment Advisors's portfolio in Q1 2026, its #793 holding.
  • Bell Investment Advisors first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 14 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Bell Investment Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.